As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.
27 Analysts have issued a BridgeBio Pharma Inc forecast:
27 Analysts have issued a BridgeBio Pharma Inc forecast:
Jun '25 |
+/-
%
|
||
Revenue | 236 236 |
8%
8%
|
|
Gross Profit | 227 227 |
5%
5%
|
|
EBITDA | -640 -640 |
29%
29%
|
EBIT (Operating Income) EBIT | -646 -646 |
28%
28%
|
Net Profit | -776 -776 |
71%
71%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Head office | United States |
CEO | Neil Kumar |
Employees | 728 |
Founded | 2015 |
Website | bridgebio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.